NCT05680012

Tissue Destruction and Healing in Celiac Disease

RecruitingNAINTERVENTIONAL

Trial Details

Start: 2023-07-14Est. Completion: 2027-05-01

Enrollment target: 220 participants

Locations

California Institute of Technology, Pasadena, California, United States
The University of Chicago, Chicago, Illinois, United States
Mayo Clinic, Rochester, Minnesota, United States

Contact

Sonia Kupfer, MDskupfer@bsd.uchicago.edu (773) 834-1438

Kristi Kearney, RNkkearney@bsd.uchicago.edu 773-834-7414

Other microbiome trials you might be interested in

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac DiseasePhase 2Recruiting

Celiac Disease

The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropath…

Murrieta, United StatesEst. completion Sep 15, 2026

View Trial →

Screening for Disorders of Lipid Metabolism and Familial Hyperlipidemia in Children and Adolescents With Increased Cardiovascular Risk Due to Chronic Diseases Such as Congenital Heart Disease, Chronic Inflammatory Bowel Disease, Celiac Disease and Rheumatic DisordersRecruiting

Lipid Metabolism DisordersLipid Metabolism, Inborn ErrorsCongenital Heart DiseaseInflammatory Bowel Disease (IBD)Rheumatic DiseasesCeliac Disease in ChildrenCeliac Disease in Adolescents

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.